ASTRAZENECA PLC (AZN) Form 6-K — Sep 1, 2026
AstraZeneca PLC announced that debt securities totaling EUR 2.55 billion have been admitted to trading on the London Stock Exchange Main Market as of 1 September 2026. The notes were issued by AstraZeneca Finance LLC, the company's wholly owned financing subsidiary. The offering comprises four tranches: EUR 700 million of 3.402% notes due 1 March 2030, EUR 600 million of 3.652% notes due 1 September 2032, EUR 500 million of 3.923% notes due 1 September 2035, and EUR 750 million of 4.169% notes due 1 September 2038.
Key figures
- Debt Amount
- 2550000000
- Interest Rate
- 3.402% to 4.169% across four tranches
- Maturity Date
- 1 September 2038 (latest tranche)
- Currency
- EUR
- Tranche 2030
- EUR 700,000,000 3.402% Notes due 1 March 2030 (ISIN XS3484302206)
- Tranche 2032
- EUR 600,000,000 3.652% Notes due 1 September 2032 (ISIN XS3484302461)
- Tranche 2035
- EUR 500,000,000 3.923% Notes due 1 September 2035 (ISIN XS3484302545)
- Tranche 2038
- EUR 750,000,000 4.169% Notes due 1 September 2038 (ISIN XS3484302628)
- Listing venue
- Main Market for listed securities of the London Stock Exchange
- Admission date
- 1 September 2026
- Number of series
- 4
- Base prospectus date
- 9 June 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.